- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01678209
Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The specific aims of this project are to use functional magnetic resonance imaging (fMRI) to determine the significance of activation changes over treatment related to clinical improvement, and the impact of treatment on neural connectivity within and between the anti-correlated frontostriatal 'task-positive' circuit and cingulate-precuneus 'task-negative' network. Our central hypotheses are that clinical improvement is associated with: (i) normalization of reduced connectivity of regions within the 'task-positive' network, with resultant increased inhibition of motor cortex, and (ii) normalization of low task-related connectivity in regions within the task-negative network for MPH and the 'task-positive' network for ATX.
This research proposes to test a model which posits a neurophysiological basis of mechanisms of response to stimulant and non-stimulant medications, and fits with our long term objectives of being able to match treatments to individual patients. Testing this model requires large samples of youth scanned using fMRI before and after treatment, and matched healthy controls also scanned twice. We will use an innovative network-based approach to study the effects of treatment, building on results from our current fMRI treatment study, and incorporating new theoretical approaches to understanding ADHD and its treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
General inclusion criteria for subjects with ADHD and healthy controls are:
- aged 7-17 years;
- Wechsler Intelligence Scale for Children (WISC) scores ≥ 75;
- informed consent and assent to study participation.
Specific inclusion criteria for youth with ADHD are:
- diagnosis of ADHD, any subtype, determined by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Aged Children-Present and Lifetime Versions (K-SADS-PL);
- ADHD Rating Scale-IV-Parent Version: Investigator Administered (ADHD-RSIV) total score ≥ 1.5 SD above age and gender means for subtype
- Clinical Global Impressions-ADHD-Severity (CGI-S) score > 4;
- ADHD must be the primary diagnosis and focus of treatment, and the treatments offered in the study must not be contraindicated for the comorbid disorder.
Exclusion Criteria:
General exclusion criteria are:
- history of head injury with loss of consciousness or any CNS disease that is likely to affect brain function;
- diagnosis of autism or pervasive developmental, psychotic, major mood, and Tourette's disorder;
- alcohol or drug abuse in the past 3 months or a positive urinary toxic screen on initial evaluation;
- use of psychotropic medication within 2 weeks of the study (8 weeks for fluoxetine);
- pre-existing medical or psychological condition which precludes being in the scanner (e.g., claustrophobia, morbid obesity);
- metal in the body that precludes scanning (e.g., braces, metal plate);
- positive urine pregnancy test.
Specific exclusion criteria for the treatment trial include:
- previous unsuccessful trial of MPH or ATX that was adequately dosed (≥ 1 mg/kg for MPH or 1.0 mg/kg for ATX) and of adequate duration (≥ 4 weeks);
- abnormal findings on physical exam, or vital signs
- pulse and blood pressure > 95% of age and gender mean;
- inability to swallow capsules;
- weight is < 20 kg or > 85 kg.
Specific exclusion criteria for control youth include:
- no past history or current diagnosis of any psychiatric disorder, determined by the K-SADS-PL interview;
- ADHD-RS-IV and CBCL scores for each symptom domain ≤ 1 SD of age and gender means.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: fMRI scans
Healthy Control Group: will receive initial evaluation, and 2 fMRI (functional magnetic resonance imaging) scans each 6-8 weeks apart
|
2 fMRI scans 6-8 weeks apart
|
Experimental: Atomoxetine arm
These subjects will receive initial evaluation and baseline fMRI scan, flexible dose titration with atomoxetine for 6-8 weeks, and fMRI postscan, with optional post study stabilization visits.
|
2 fMRI scans 6-8 weeks apart
Flexible dose titration with atomoxetine prescribed at weekly visits for 6-8 weeks
Other Names:
|
Experimental: Methylphenidate arm
Subjects will receive initial evaluation, baseline fMRI scan, flexible dose titration with methylphenidate (Concerta) for 6-8 weeks, and fMRI scan post treatment.
|
2 fMRI scans 6-8 weeks apart
Flexible dose titration with methylphenidate for 6-8 weeks, with optional post study stabilization visits.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Correct Inhibition in Participants Assessed With the Go-No go Task
Time Frame: Baseline and at 6 weeks
|
Comparison of Go-Nogo at 6 weeks from baseline.
Performance on a go-nogo task inside the scanner (fMRI).
In the go/no-go task, participants respond to certain stimuli ("go" stimuli) and make no response for others ("no-go" stimuli).
|
Baseline and at 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adult Attention Deficit Hyperactivity Disorder Investigator Symptom Rating Scale (ADHD-RS)
Time Frame: 8 weeks
|
ADHD-RS is an 18-item list of core ADHD symptoms, each item are scored on a 4-point scale from 0-3, with total 0-54, with higher score indicating more symptoms.
|
8 weeks
|
Clinical Global Impressions-Severity (CGI-S)
Time Frame: up to 6 weeks
|
a clinician rated measure of symptom severity.
CGI-S is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis.
Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
|
up to 6 weeks
|
Response Time in Attention Networks Test (ANT)
Time Frame: baseline and at 6 weeks
|
A neuropsychological assessment of attention compared at 6 weeks from baseline by looking at response time.
The ANT is a task designed to test three attentional networks in children and adults: alerting, orienting, and executive control.
The response time were summed.
|
baseline and at 6 weeks
|
Continuous Performance Test (CPT)
Time Frame: baseline and at 6 weeks
|
A neuropsychological assessment of attention compared at 6 weeks from baseline.
CPT is a task-oriented computerized assessment of attention-related problems.This score indicates the number of times the client responded but no target was presented.
A fast reaction time and high commission error rate points to difficulties with impulsivity.
A slow reaction time with high commission and omission errors, indicates inattention in general.
Scores are compared with the normative scores for the age, group and gender of the person being tested and represented as a commissioned T-score.
The T-score indicates the degree to which performance in CPT task is higher or lower than the performance of a healthy individual matched in age.
A T-score of 50 is equal to the mean and is considered normal.
Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.
Higher values are indicative of more attention-related problems.
|
baseline and at 6 weeks
|
Digit Span
Time Frame: baseline and at 6 weeks
|
A cognitive/neuropsychological measure of auditory/verbal working memory compared at 6 weeks from baseline.
Digit Span.
Memory span is the longest list of items that a person can repeat back in correct order immediately after presentation on 50% of all trials.
Items may include words, numbers, or letters.
The task is known as digit span when numbers are used.
Memory span is a common measure of short-term memory.
A digit-span task is used to measure working memory's number storage capacity.The item score is the sum of the scores on the two trials for that item (range=0-2).
The total raw score for backwards digit span is the sum of the item scores; maximum backwards digit span total raw score is 0-16 points.
Higher score indicates better health outcomes.
|
baseline and at 6 weeks
|
Finger Windows
Time Frame: baseline and at 6 weeks
|
A neuropsychological measure of motor skill and visual-spatial working memory compared at 6 weeks from baseline.
The Finger Windows subtest is a measure of nonverbal, rote sequential recall.
scaled scores ranging from 1 to 19, with higher score indicating better attention or concentration.
|
baseline and at 6 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Kurt Schulz, PhD, Icahn School of Medicine at Mount Sinai
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Adolescent
- Treatment
- Imaging
- Concerta
- Functional Magnetic Resonance Imaging
- Attention Deficit Hyperactivity Disorder
- Brain Imaging
- Youth
- Methylphenidate
- Medication
- Drug
- Stimulant
- Non-stimulant
- Atomoxetine
- Strattera
- MACRO
- Brain scan
- Response inhibition
- Inattentive
- Hyperactive
- Combined
- Medication Treatment
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Neurologic Manifestations
- Dyskinesias
- Attention Deficit and Disruptive Behavior Disorders
- Neurodevelopmental Disorders
- Attention Deficit Disorder with Hyperactivity
- Hyperkinesis
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Adrenergic Uptake Inhibitors
- Methylphenidate
- Atomoxetine Hydrochloride
Other Study ID Numbers
- GCO 11-0161
- 5R01MH095766-02 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ADHD
-
The Hong Kong Polytechnic UniversityRecruiting
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)Recruiting
-
VIZO Specs LtdRecruiting
-
Loewenstein HospitalWingate InstituteRecruiting
-
Florida State UniversityRecruiting
-
Florida International UniversityRecruiting
-
Region Örebro CountyRecruiting
-
Johns Hopkins UniversityWithdrawn
-
Tris Pharma, Inc.Premier Research Group plcCompleted
Clinical Trials on fMRI scans
-
Centre Hospitalier Universitaire de NīmesRecruitingLow Back Pain | Chronic Low Back PainFrance
-
FLUIDDA nvTerminatedBronchiolitis Obliterans | Lung Transplant RejectionBelgium
-
National Cancer Institute (NCI)CompletedNeurofibromatosis | MPNSTUnited States
-
State University of New York - Upstate Medical...Enrolling by invitation
-
Smart Alfa Teknoloji San. ve Tic. A.S.Ankara UniversityCompletedUltrasound Imaging of Anatomical Structures | Nerve BlockTurkey
-
University Hospital Plymouth NHS TrustUniversity of PlymouthCompletedBronchopulmonary Dysplasia | Right Ventricular Dysfunction | In the Perinatal PeriodUnited Kingdom
-
University of Wisconsin, MadisonNational Institute of Neurological Disorders and Stroke (NINDS); National Institutes...CompletedBrain InjuriesUnited States, United Kingdom, Australia
-
Kasr El Aini HospitalCompletedCataract | Primary Open-angle GlaucomaEgypt
-
University of Colorado, DenverNational Heart, Lung, and Blood Institute (NHLBI)CompletedWounded Spirits, Ailing Hearts: Post-Traumatic Stress Disorder and Cardiovascular Disease in IndiansHeart Diseases | Cardiovascular Diseases
-
The First Hospital of Hebei Medical UniversityUnknown